Page 105 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Novel senescence-based melanoma risk model

compared to Cluster 1, showed lower risk scores. To assess Author contributions
the reliability of the model, both an internal validation set
and external datasets (GSE65904 and GSE19234) from the Conceptualization: Lanlan Liu, Yunjin Xie, Mingzhu Yin
GEO database were used. In both datasets, stratification of Formal analysis: Yiting Feng, Lanlan Liu
patients based on risk scores calculated by the risk model, Investigation: Yiting Feng, Lanlan Liu, Yunjin Xie
Methodology: Lanlan Liu, Yunjin Xie
along with immune profile analysis using CIBERSORT, Writing–original draft: Yiting Feng, Yunjin Xie
revealed that the low-risk group was characterized by an Writing–review & editing: Yiting Feng, Lanlan Liu,
immunoactivated microenvironment, which was associated Mingzhu Yin
with better prognosis. These results indicate that the risk
score not only predicts survival but also reflects the immune Ethics approval and consent to participate
activation status of the TME, providing a potential link
between senescence-related gene expression and immune- Not applicable.
mediated tumor control. The robust performance of the risk Consent for publication
model across multiple datasets highlights its potential utility
in clinical practice. By stratifying melanoma patients into Not applicable.
distinct risk categories, the model could guide personalized
treatment strategies, such as identifying high-risk patients Availability of data
who could benefit from more aggressive therapies or The RNA-seq data and clinical information such as stage,
immunotherapy combinations. Furthermore, integrating T stage, N stage, M stage, gender, age, OS, and OS time
this risk model with other molecular and clinical biomarkers of TCGA SKCM were downloaded from the UCSC Xena
could enhance its predictive accuracy and facilitate the database (https://xenabrowser.net/datapages/). The raw
development of precision medicine approaches in melanoma. signal intensity values and survival data of GSE65904 were
obtained from the (GEO, https://www.ncbi.nlm.nih.gov/
5. Conclusion geo/). The aging-related genes were curated from previous
This study highlights the significant prognostic value of studies. 25-27
senescence-related genes in SKCM. The developed risk References
model, validated by both internal and external datasets,
offers a promising approach for patient stratification 1. Sun Y, Shen Y, Liu Q, et al. Global trends in melanoma
and personalized treatment in melanoma. Future studies burden: A comprehensive analysis from the global
exploring the underlying mechanisms by which senescence- burden of disease study, 1990-2021. J Am Acad Dermatol.
2025;92(1):100-107.
related genes influence immune microenvironments and
tumor progression could provide further insights into new doi: 10.1016/j.jaad.2024.09.035
therapeutic targets for melanoma treatment. 2. Arnold M, Singh D, Laversanne M, et al. Global burden
of cutaneous melanoma in 2020 and projections to 2040.
Acknowledgments JAMA Dermatol. 2022;158(5):495-503.

None. doi: 10.1001/jamadermatol.2022.0160
Funding 3. Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in
China 2019-2021: A multicenter, population-based study.
This work was supported in part by General project of J Natl Cancer Cent. 2024;4(3):203-213.
Chongqing Joint Fund of Science and Technology (Grant doi: 10.1016/j.jncc.2024.06.005
No. CSTB2024NSCQ-LMX0016) [Y.X.]; Chongqing 4. Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of
Wanzhou PhD “through train” Research Project (Grant immune activation and regulation: Lessons from melanoma.
No. Wzstc20230402) [M.Y.]. Nat Rev Cancer. 2022;22(4):195-207.

Conflict of interest doi: 10.1038/s41568-022-00442-9

Mingzhu Yin is an Editor in Chief of this journal but was 5. Long GV, Swetter SM, Menzies AM, Gershenwald JE,
not in any way involved in the editorial and peer-review Scolyer RA. Cutaneous melanoma. Lancet.
2023;402(10400):485-502.
process conducted for this paper, directly or indirectly.
Separately, other authors declared that they have no known doi: 10.1016/S0140-6736(23)00821-8
competing financial interests or personal relationships that 6. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety
could have influenced the work reported in this paper. of lifileucel, a one-time autologous tumor-infiltrating

Volume 9 Issue 3 (2025) 97 doi: 10.36922/ejmo.8574